Nuvectis Pharma (NASDAQ:NVCT) Price Target Lowered to $11.00 at HC Wainwright

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) had its target price cut by analysts at HC Wainwright from $21.00 to $11.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 64.42% from the company's previous close. HC Wainwright also issued estimates for Nuvectis Pharma's Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.87) EPS and FY2028 earnings at ($2.24) EPS.

Nuvectis Pharma Price Performance

Shares of NVCT traded down $0.02 during mid-day trading on Tuesday, hitting $6.69. The company's stock had a trading volume of 28,728 shares, compared to its average volume of 114,701. The firm has a 50-day moving average price of $6.26 and a 200 day moving average price of $6.41. Nuvectis Pharma has a fifty-two week low of $4.44 and a fifty-two week high of $12.10. The stock has a market capitalization of $129.26 million, a price-to-earnings ratio of -5.77 and a beta of 0.22.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, equities analysts anticipate that Nuvectis Pharma will post -1.01 EPS for the current fiscal year.

Remove Ads

Insider Activity

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri purchased 240,000 shares of the stock in a transaction dated Friday, February 7th. The shares were acquired at an average price of $5.00 per share, for a total transaction of $1,200,000.00. Following the completion of the acquisition, the insider now owns 2,884,121 shares of the company's stock, valued at $14,420,605. This represents a 9.08 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have bought 261,500 shares of company stock worth $1,300,825 over the last 90 days. 35.78% of the stock is owned by company insiders.

Institutional Trading of Nuvectis Pharma

Several large investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC bought a new stake in Nuvectis Pharma in the fourth quarter worth $34,000. Nations Financial Group Inc. IA ADV acquired a new position in shares of Nuvectis Pharma during the 3rd quarter valued at about $63,000. Baxter Bros Inc. raised its stake in shares of Nuvectis Pharma by 20.0% in the 4th quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock valued at $81,000 after acquiring an additional 2,500 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Nuvectis Pharma in the 4th quarter worth approximately $103,000. Finally, Oppenheimer & Co. Inc. bought a new stake in Nuvectis Pharma during the fourth quarter worth approximately $135,000. 96.77% of the stock is owned by institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.